Thanks to a partnership with GLP-certified Analytical Laboratory, we offer bioanalytical services in qualitative and quantitative determination of drugs in biological samples, such as biological fluids (blood, serum, plasma, saliva, urine) or tissues. Analyses are performed mainly using high performance liquid chromatography coupled with mass spectrometry (microLC-MS/MS or UHPLC-MS).

The offer includes a full bioanalysis in accordance with the GLP requirements:

  • development of bioanalytical methods for qualitative and quantitative determination of the drug and/or it’s metabolites in biological material
  • bioanalytical method validation according to EMA or FDA guidelines
  • sample preparation (including pre-treatment in place of the volunteers, if needed)
  • development of an analytical report, in accordance with EMA/FDA guidelines and the customer needs

Validated Bioanalytical Methods

Target Matrix Technique Concentration range
Aniracetam Human plasma (K2EDTA) LC-MS/MS 0.05–20 ng/mL
4-p-Anisamidobutyric acid (metabolite of Aniracetam) Human plasma (K2EDTA) LC-MS/MS 0.05–20 µg/mL
Anti IIa activity Rat plasma Chromogenic assay 0.141–0.885 IU/mL
Anti IIa activity Human plasma (sodium citrate) Chromogenic assay 0.0051–0.3024 IU/mL
Anti Xa activity Rat plasma Chromogenic assay 0.166–0.997 IU/mL
Anti Xa activity Human plasma (sodium citrate) Chromogenic assay 0.025–0.997 IU/mL
TFPI activity Human plasma (sodium citrate) Chromogenic assay 0.020–0.200 U/mL
Capecitabine Human plasma (K2EDTA) LC-MS 0.1–5 µg/mL
Cinnarizine Human plasma (K2EDTA) LC-MS/MS 1 -100 ng/mL
Darunavir Human plasma (K2EDTA) LC-MS/MS 5–10 000 ng/mL
Dimenhydrinate Human plasma (K2EDTA) LC-MS/MS 5–10 000 ng/mL
Darunavir Human plasma (K2EDTA) LC-MS/MS 0.1 – 50 ng/mL
Drotaverine Human plasma (K2EDTA) LC-MS 5–1000 ng/mL
Hyodeoxycholic acid Human plasma (K2EDTA) LC-MS 0.1–300 µg/mL
Hyodeoxycholic acid Human serum (K2EDTA) LC-MS 0.1–300 µg/mL
Irinotecan Mouse plasma LC-MS 50–300 ng/mL
7-Ethyl-10-hydroxy-camptothecin (metabolite of Irinotecan) Human plasma (K2EDTA) LC-MS/MS 5–10 000 ng/mL
Darunavir Mouse plasma LC-MS 30–300 ng/mL
Lorediplon Human plasma (Na-Heparin) LC-MS/MS 0.1–50 ng/mL
Oseltamivir Human plasma (potassium oxalate / sodium fluoride) LC-MS/MS 0.5–100 ng/mL
Sulfadiazine Human plasma (K2EDTA) LC-MS 0.075–10 µg/mL
Sulfadiazine Human urine LC-MS 0.25–5 µg/mL
3-Demethyl Thiocolchicine 3-O-β-D-Glucuronide (metabolite of Thiocolchicoside) Human plasma (K2EDTA) LC-MS/MS 0.5–100 ng/mL
Zolpidem Human plasma (Na-Heparin) LC-MS/MS 1–250 ng/mL

Methods under development

Target Matrix Technique Concentration range
Lopinavir Human plasma (K2EDTA) LC-MS/MS -
Cephalexin Human plasma (potassium oxalate / sodium fluoride) LC-MS/MS -
Clomipramine Human plasma (K2EDTA) LC-MS/MS -
Nicotine Human plasma LC-MS/MS -
Follow us on LinkedIn
Follow us on LinkedIn
Follow us on Twitter
Follow us on Twitter
Follow us on LinkedIn
Follow us on YouTube
Email us
Send us an e-mail